Illexcor Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $13M

  • Investors
  • 4

Illexcor Therapeutics General Information

Description

Operator of a biopharmaceutical company intended for the discovery and development of innovative oral therapies for sickle cell disease. The company develops oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits for sickle cell disease, enabling patients living with hematologic diseases to improve their lives and provide effective and disease-modifying treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11924 Evening Loop
  • Henrico, VA 23233
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 11924 Evening Loop
  • Henrico, VA 23233
  • United States
+1 (650)

Illexcor Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Illexcor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A) 07-May-2026 $13M Completed Startup
7. Seed Round 12-Mar-2025 Completed Startup
6. Grant 01-Jan-2025 Completed Startup
5. Grant 01-Jan-2024 Completed Startup
4. Grant 01-Jan-2023 Completed Startup
3. Grant 01-Jan-2023 Completed Startup
2. Grant 01-Jan-2021 $298K Completed Startup
1. Grant 01-Jan-2020 $600K Completed Startup
To view Illexcor Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Illexcor Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Illexcor Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Janus Henderson Investors Asset Manager Minority
Zynext Ventures Corporate Venture Capital Minority
U.S. Department of Health and Human Services Government
National Institutes of Health Government
To view Illexcor Therapeutics’s complete investors history, request access »

Illexcor Therapeutics FAQs

  • When was Illexcor Therapeutics founded?

    Illexcor Therapeutics was founded in 2020.

  • Where is Illexcor Therapeutics headquartered?

    Illexcor Therapeutics is headquartered in Henrico, VA.

  • What is the size of Illexcor Therapeutics?

    Illexcor Therapeutics has 7 total employees.

  • What industry is Illexcor Therapeutics in?

    Illexcor Therapeutics’s primary industry is Drug Discovery.

  • Is Illexcor Therapeutics a private or public company?

    Illexcor Therapeutics is a Private company.

  • What is Illexcor Therapeutics’s current revenue?

    The current revenue for Illexcor Therapeutics is .

  • How much funding has Illexcor Therapeutics raised over time?

    Illexcor Therapeutics has raised $13M.

  • Who are Illexcor Therapeutics’s investors?

    Janus Henderson Investors, Zynext Ventures, U.S. Department of Health and Human Services, and National Institutes of Health have invested in Illexcor Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process